UGT2B17 modifies drug response in chronic lymphocytic leukaemia.

导出 OA

翻译打印收藏纠错

作者： Eric P,Allain ^[1] ; Michèle,Rouleau ^[1] ; Katrina,Vanura ^[2] ; Sophie,Tremblay ^[1] ; Joanie,Vaillancourt ^[1] ; Vincent,Bat ^[1] ; Patrick,Caron ^[1] ; Lyne,Villeneuve ^[1] ; Adrien,Labriet ^[1] ; Véronique,Turcotte ^[1] ; Trang,Le ^[2] ; Medhat,Shehata ^[2] ; Susanne,Schnabl ^[2] ; Dita,Demirtas ^[2] ; Rainer,Hubmann ^[2] ; Charles,Joly-Beauparlant ^[3] ; Arnaud,Droit ^[3] ; Ulrich,Jäger ^[2] ; Philipp B,Staber ^[2] ; Eric,Lévesque ^[4] ; Chantal,Guillemette ^[5]

作者单位： Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada. ^[1] Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ^[2] CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, QC, Canada. ^[3] CHU de Québec Research Centre, Department of Medicine, Faculty of Medicine, Laval University, Québec, QC, Canada. ^[4] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada. chantal.guillemette@crchudequebec.ulaval.ca. ^[5] Canada Research Chair in Pharmacogenomics, Québec, QC, Canada. chantal.guillemette@crchudequebec.ulaval.ca. ^[6]